Reports
Sale
North America Gene Expression Market Size, Share, Growth: By Technology: Polymerase Chain Reaction, Next Generation Sequencing, Microarrays, Northern Blotting, Others; By Product Type: Instruments, Reagents and Consumables, Services; By End User; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
North America Gene Expression Market Outlook
North America gene expression market size was valued at USD 2.03 billion in 2023, driven by the rapid advancement in the field of genomics in the region. The market is expected to grow at a CAGR of 8.5% during the forecast period of 2024-2032, with the values likely to rise from USD 2.21 billion in 2024 to USD 4.25 billion by 2032.
Key Takeaways
- In 2024, new cancer cases are projected to surpass 2 million in a year in the United States. The rising demand for precision oncology, fuelled by growing incidence rates of cancer, is expected to drive market growth.
- In December 2023, Neurogene Inc., concluded a merger deal with Neoleukin Therapeutics, Inc. The partnership worth USD 200 million is intended towards developing differentiated genetic therapies for the treatment of complex neurological diseases.
- In March 2023, Illumina Inc., announced the launch of its new Illumina Complete Long Read technology called Illumina Complete Long Read Prep, Human. It the first-ever product that allows access to both long- and short-read data on the same Illumina instrument.
North America Gene Expression Market Analysis
The market growth is driven by advancements in gene expression analysis, which can help to define tumor subtypes and offer a more targeted approach towards cancer treatment. The rising incidence of cancer coupled with the growing patient inclination towards precision oncology is likely to augment market demand. In 2024, new cancer cases are projected to surpass 2 million in a year in the United States, with the estimates suggesting 5,500 cancer diagnoses in a day and over 611,000 deaths in the year. Insights from gene expression analysis can aid oncologists in providing tailored treatment to the huge patient population, thereby driving North America gene expression market growth.
In December 2023, Neurogene Inc., a United States-based biotechnology company specializing in genetic medicines, concluded a merger deal with Neoleukin Therapeutics, Inc., a biopharmaceutical company creating next-generation immunotherapies. The merged business, expected to hold cash worth USD 200 million on closure, plans to focus on the development of differentiated genetic therapies for the treatment of complex neurological diseases including Rett Syndrome. Such merger and acquisition activities are expected to propel the demand for gene expression analysis tools and services, which is likely to boost the market share in the region.
The market is witnessing technological innovations in DNA-sequencing and array-based technologies, which are anticipated to drive North America gene expression market demand. In March 2023, Illumina Inc., announced the launch of its new Illumina Complete Long Read technology called Illumina Complete Long Read Prep, Human. Designated as the first-ever product that allows access to both long- and short-read data on the same Illumina instrument, it is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing System. Illumina Complete Long Reads demonstrated accuracy and flexibility, as evidenced by early customer data. The launch of such technologically advanced products which address the limitations associated with long-read technologies and reduce associated costs is likely to support North America gene expression market share in the forecast period.
Other factors that drive the market are the increased application of gene expression profiling in understanding the molecular mechanisms in various diseases, biomarker discovery, drug development, and precision medicine, among others. Moreover, the advancement in healthcare infrastructure and increased investment in research and development are also expected to boost market size.
North America Gene Expression Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Technology | Polymerase Chain Reaction, Next Generation Sequencing, Microarrays, Northern Blotting, Others |
| Product Type | Instruments, Reagents and Consumables, Services |
| End User | Drug Discovery & Development, Diagnostic Laboratories, Academic Research Centers, Others |
| Countries | United States of America, Canada |
North America Gene Expression Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- GE Healthcare
- QIAGEN N.V.
- Life Technologies
- Agilent Technologies
- PerkinElmer
- Bio-Rad Laboratories
- Roche Diagnostics
- Oxford Gene Technology
- Luminex Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Product Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Gene Expression Market Overview
3.1 North America Gene Expression Market Historical Value (2017-2023)
3.2 North America Gene Expression Market Forecast Value (2024-2032)
4 North America Gene Expression Market Landscape*
4.1 North America Gene Expression: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Gene Expression: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Product Type
5 North America Gene Expression Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Gene Expression Market Segmentation (2017-2032)
6.1 North America Gene Expression Market (2017-2032) by Technology
6.1.1 Market Overview
6.1.2 Polymerase Chain Reaction
6.1.3 Next Generation Sequencing
6.1.4 Microarrays
6.1.5 Northern Blotting
6.1.6 Others
6.2 North America Gene Expression Market (2017-2032) by Product Type
6.2.1 Market Overview
6.2.2 Instruments
6.2.3 Reagents and Consumables
6.2.4 Services
6.3 North America Gene Expression Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Drug Discovery & Development Centers
6.3.3 Diagnostic Laboratories
6.3.4 Academic Research Centers
6.3.5 Others
6.4 North America Gene Expression Market (2017-2032) by Countries
6.4.1 Market Overview
6.4.2 United States of America
6.4.3 Canada
7 United States of America Gene Expression Market (2017-2032)
7.1 United States of America Gene Expression Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Polymerase Chain Reaction
7.1.3 Next Generation Sequencing
7.1.4 Microarrays
7.1.5 Northern Blotting
7.1.6 Others
7.2 United states of America Gene Expression Market (2017-2032) by Product Type
7.2.1 Market Overview
7.2.2 Instruments
7.2.3 Reagents and Consumables
7.2.4 Services
7.2.5 Others
7.3 United States of America Gene Expression Market (2017-2032) by End User
7.3.1 Market Overview
7.3.2 Drug Discovery & Development Centers
7.3.3 Diagnostic Laboratories
7.3.4 Academic Research Centers
8 Canada Gene Expression Market (2017-2032)
8.1 Canada Gene Expression Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Polymerase Chain Reaction
8.1.3 Next Generation Sequencing
8.1.4 Microarrays
8.1.5 Northern Blotting
8.1.6 Others
8.2 Canada Gene Expression Market (2017-2032) by Product Type
8.2.1 Market Overview
8.2.2 Instruments
8.2.3 Reagents and Consumables
8.2.4 Services
8.2.5 Others
8.3 Canada Gene Expression Market (2017-2032) by End User
8.3.1 Market Overview
8.3.2 Drug Discovery & Development Centers
8.3.3 Diagnostic Laboratories
8.3.4 Academic Research Centers
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Thermo Fisher Scientific Inc.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 GE Healthcare
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 QIAGEN N.V.
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Life Technologies
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Agilent Technologies
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 PerkinElmer
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Bio-Rad Laboratories
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Roche Diagnostics
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Oxford Gene Technology
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Luminex Corporation
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Gene Expression Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 2.03 billion in 2023 driven by the rapid advancement in the field of genomics in the region.
The market is anticipated to grow at a CAGR of 8.5% during the forecast period of 2024-2032, likely to reach a market value of USD 4.25 billion by 2032.
The rising prevalence of chronic diseases and the growing preference for precision medicine are fuelling the demand for the market.
One of the significant trends in the market is the rise in technological innovations in DNA sequencing and array-based technologies. In March 2023, Illumina Inc. announced the launch of Illumina Complete Long Read Prep, Human, the first-ever product that allows access to both long- and short-read data on the same Illumina instrument.
Based on the technology, the market is segmented into polymerase chain reaction, next-generation sequencing, microarrays, and northern blotting, among others.
By product type, the market is divided into instruments, reagents, and consumables, as well as services.
End users of the market are drug discovery and development, diagnostic laboratories, and academic research centers and others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Thermo Fisher Scientific Inc., GE Healthcare, QIAGEN N.V., Life Technologies, Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Roche Diagnostics, Oxford Gene Technology, and Luminex Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER